Melinda Aldrich

VUMC hosts International Lung Cancer Consortium meeting 

The consortium is coordinated by the International Agency for Research on Cancer with the aim of sharing data from ongoing lung cancer case-control and cohort studies.

Melinda Aldrich, PhD, MPH

Melinda Aldrich elected to genetics society board of directors

Aldrich uses population-based cohorts and biobanks to investigate lung cancer; her research informed guidelines for lung cancer screening.

Vanderbilt research played key role in new lung screen guidelines

The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.

Criteria for lung cancer screens may be expanded

The U.S. Preventive Services Task Force (USPSTF) is recommending two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.

The Vanderbilt team studying histoplasmosis includes (front row, from left, Heidi Chen, PhD, Melinda Aldrich, PhD, MPH, (back row, from left) Stephen Deppen, PhD, Eric Grogan, MD, MPH, and Jeffrey Blume, PhD.

Team explores fungal infection quandary in lung cancer screenings

Serving a region that lies within the tobacco belt, clinicians at Vanderbilt Health face challenges distinguishing lung cancer from histoplasmosis, a fungal infection that creates cancer-mimicking lesions in the lungs.

Genetics of lung cancer survival

Vanderbilt investigators have conducted a first-of-its-kind genome-wide association study of lung cancer survival in African-Americans.